Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (9): 1946-1947.doi: 10.4103/1673-5374.367842

Previous Articles     Next Articles

Microglial metabolic reconfiguration provides a new strategy for the treatment of Alzheimer’s disease

Lige Leng*, Jie Zhang*   

  1. Institute of Neuroscience, Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian Province, China
  • Online:2023-09-15 Published:2023-03-06
  • Contact: Jie Zhang, PhD, jiezhang@xmu.edu.cn; Lige Leng, PhD, lenglige@xmu.edu.cn.
  • Supported by:
    This work was supported by the National Nature Science Foundation of China (Nos. 91849205, 81925010, and U1905207 to JZ; Nos. 81801337 and 82071520 to LL; No. 92149303 to JZ); The National Key Research and Development Program of China (No. 2021YFA1101402 to JZ); The Fundamental Research Funds for the Central Universities (Nos. 20720190118 and 20720180049 to JZ; No. 20720190075 to LL); Nature Science Foundation of Fujian Province (No. 2019J05006 to LL); Xiamen Youth Innovation Fund (No. 3502Z20206031 to LL).  

PDF

69

Abstract: Alzheimer’s disease (AD) shares multiple characteristics of metabolic diseases: AD is an age-associated neurodegenerative disease characterized by progressive loss of memory and cognitive functions, which is classically manifested by the deposition of β-amyloid (Aβ) plaques, the neurofibrillary tangles, and neuronal loss. Mounting evidence also suggests that AD shares multiple characteristics of metabolic diseases. The impairment in cerebral glucose metabolism and insulin resistance are considered typical features of AD and its occurrence precedes cognitive dysfunction for decades in patients.